Background: Cholesterol-lowering therapy has been related with several beneficial effects; however, its influence on oxidative stress and endothelial function is not fully elucidated.
Aims: To investigate the effect of simvastatin and ezetimibe on mitochondrial function and leukocyte-endothelium interactions in polymorphonuclear cells of hyperlipidemic patients.
Methods: Thirty-nine hyperlipidemic patients were randomly assigned to one of two groups: one received simvastatin (40 mg/day) and the other received ezetimibe (10 mg/day) for 4 weeks, after which both groups were administered combined therapy for an additional 4-week period. Lipid profile, mitochondrial parameters (oxygen consumption, reactive oxygen species (ROS) and membrane potential), glutathione levels, superoxide dismutase activity, catalase activity and leukocyte/endothelial cell interactions and adhesion molecules -VCAM-1, ICAM-1, E-selectin, were evaluated.
Results: An improvement in lipid profile was observed after administration of simvastatin or ezetimibe alone (LDLc: -40.2 vs -19.6%, respectively), though this effect was stronger with the former (p < 0.001), and a further reduction was registered when the two were combined (LDLc: -50.7% vs -56.8%, respectively). In addition to this, simvastatin, ezetimibe and simvastatin + ezetimibe significantly increased oxygen consumption, membrane potential and glutathione content, and decreased levels of ROS, thereby improving mitochondrial function. Furthermore, simvastatin + ezetimibe increased catalase activity. In addition, simvastatin and simvastatin/ezetimibe improved leukocyte/endothelium interactions by decreasing leukocyte rolling and adhesion and increasing leukocyte rolling velocity. Finally, simvastatin, ezetimibe and simvastatin + ezetimibe reduced levels of the adhesion molecule ICAM-1, and ezetimibe + simvastatin significantly decreased levels of E-selectin.
Conclusion: Co-administration of simvastatin and ezetimibe has an additive cholesterol-lowering effect and beneficial consequences for mitochondrial function and leukocyte/endothelium interactions in leukocytes of hypercholesterolemic patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.atherosclerosis.2016.01.044 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S).
Lancet
December 2024
School of Medicine, University of Western Australia, Perth, WA, Australia; Cardiometabolic Service, Department of Cardiology and Internal Medicine, Royal Perth Hospital, Perth, WA, Australia.
Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor for atherosclerotic cardiovascular disease. Safe and effective statins remain the cornerstone of therapeutic approach for this indication, including for children with genetic dyslipidaemia, and are one of the most widely prescribed drugs in the world. However, despite the affordability of generic statins, they remain underutilised worldwide.
View Article and Find Full Text PDFEvaluation of the role of metabolizing enzymes and transporter variants in ezetimibe pharmacokinetics.
Front Pharmacol
October 2024
Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria La Princesa (IIS-Princesa), Madrid, Spain.
Article Synopsis
- Ezetimibe is a drug that helps reduce cholesterol levels by blocking its absorption in the intestines, but there are currently no established pharmacogenetic guidelines for its use.
- The study involved 96 healthy participants from different trials and focused on 49 genetic variants in 22 genes to determine their impact on ezetimibe's effects.
- Although no strong links were found between genetic variants and ezetimibe's metabolism, some variants showed potential significance in further analyses, suggesting the need for more research in the future.
Impact of sex-specific thresholds for low flow in assessment of prognosis in concordantly and discordantly graded aortic valve stenosis.
Eur Heart J Cardiovasc Imaging
October 2024
Department of Clinical Science, University of Bergen, Bergen, Norway.
Objective: Sex-specific low flow was recently defined as stroke volume index (SVi) ≤40 ml/m² in men and ≤32 ml/m² in women. We tested the prognostic association of these cut-offs in patients with aortic stenosis (AS) with concordantly and discordantly graded AS (CGASEL and DGASEL) based on pressure recovery adjusted aortic valve area (energy loss, EL).
Methods: Data from 1351 patients with asymptomatic AS, peak jet velocity <4m/s and preserved left ventricular ejection fraction enrolled in the Simvastatin and Ezetimibe in AS study was used.
Associations of different types of statins with the risk of open-angle glaucoma: a systematic review and network meta-analysis.
Graefes Arch Clin Exp Ophthalmol
August 2024
School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Article Synopsis
- This study investigated how different statins affect the risk of developing glaucoma, a serious eye condition.
- The researchers conducted a thorough analysis of data from various medical databases covering a wide range of cholesterol-lowering medications and their relationship with glaucoma.
- Results showed that rosuvastatin, simvastatin, and pravastatin significantly increased the risk of glaucoma compared to a placebo, suggesting caution for patients at risk when these statins are prescribed.
Analysis of composite time-to-event endpoints in cardiovascular outcome trials.
Clin Trials
October 2024
Clinical Biostatistics, Merck & Co., Inc., North Wales, PA, USA.
Composite time-to-event endpoints are commonly used in cardiovascular outcome trials. For example, the IMPROVE-IT trial comparing ezetimibe+simvastatin to placebo+simvastatin in 18,144 patients with acute coronary syndrome used a primary composite endpoint with five component outcomes: (1) cardiovascular death, (2) non-fatal stroke, (3) non-fatal myocardial infarction, (4) coronary revascularization ≥30 days after randomization, and (5) unstable angina requiring hospitalization. In such settings, the traditional analysis compares treatments using the observed time to the occurrence of the first (i.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!